Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 28, 2007

Charles River to Construct Preclinical Services Facility in Quebec

  • Charles River Laboratories reports that it intends to build a new facility in Sherbrooke, Quebec, to support the company’s expanding preclinical services business. The site will provide drug discovery and development services to the pharmaceutical and biopharmaceutical industry.

    The new building will be approximately 300,000 sq. ft. The first phase, which is scheduled to open by the first quarter of 2009, will represent approximately 25% of the space and will be dedicated to one or two clients. Charles River says that the remaining construction will be dependent on market demand.

    “Our goal was to identify a location similar to Montreal, equally convenient for our customers, where we could situate this new facility,” comments Christopher Perkin, corporate vp and president, Canadian preclinical services. “Sherbrooke is ideal for many reasons, including its proximity to world-class educational institutions offering well-educated laboratory and life sciences graduates as well as opportunities for collaborations and access to cutting-edge technology.”



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »